Subject Areas on Research
- A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
- Cimetidine versus antacids in the prevention of stress erosions in critically ill patients.
- Disparate adjuvant properties among three formulations of "alum".
- Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.
- QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
- Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.